I am a board-certified medical oncologist who is dedicated to improving the lives of patients with genitourinary tumors. My primary area of expertise is kidney cancer (renal cell carcinoma) and testicular cancer (germ-cell tumor). For more than 25 years, I have used my skills as a clinician to provide high-quality and compassionate care for cancer patients at Memorial Sloan Kettering.
Read more Read less
In addition to providing patients with the highest standard of medical care, I have led more than 75 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical trials. My research has helped to identify eight targeted drugs — sunitinib (Sutent®), pazopanib (Votrient®), axitinib (Inlyta®), temsirolimus (Torisel®), everolimus (Afinitor®), nivolumab (Opdivo®), cabozantinib (Cabometyx®), and lenvatinib (Lenvima®) — as effective treatments for patients with advanced kidney cancer. Also, I developed a system to aid in the prediction of treatment outcomes for patients taking medications for advanced kidney cancer; this (“MSKCC”) risk system is widely applied by physicians internationally to direct the care of patients. In the area of testicular cancer, my patient care and research efforts focus on developing better treatments for patients with difficult-to-treat tumors.
On both a national and international level, I work to improve the quality and delivery of cancer care for individuals diagnosed with kidney cancer and testicular cancer. I chair the National Comprehensive Care Network Kidney Cancer Guidelines Panel. I have published more than 500 original articles, scientific reviews, chapters and abstracts, and given lectures worldwide, in countries that include Japan, China, Russia, Brazil, Germany, Spain and Turkey.
I am a recipient of the Career Development Award from the National Institutes of Health; the Willet F. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering; and the Schonfeld Award from the Kidney Cancer Association, a charitable organization dedicated to kidney cancer patient advocacy.
- Clinical Expertise: Kidney Cancer; Germ Cell Tumors; Testicular Cancer; Immunotherapy
- Languages Spoken: English
- Education: MD, University of Michigan Medical School
- Residencies: Internal Medicine - North Shore University Hospital/Memorial Sloan Kettering Cancer Center
- Fellowships: Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Robert J. Motzer
- A Phase III Study Comparing Lenvatinib with Everolimus or Pembrolizumab versus Sunitinib Alone for Patients with Advanced Renal Cell Cancer
- A Phase III Study Comparing Nivolumab Immunotherapy plus Cabozantinib, Nivolumab and Ipilimumab plus Cabozantinib, and Sunitinib Alone for Patients with Untreated Advanced Kidney Cancer
- A Phase III Study of Axitinib plus Avelumab Immunotherapy versus Sunitinib Alone in Patients with Previously Untreated Advanced Kidney Cancer
- A Phase III Study of Immunotherapy versus Placebo in Patients with Localized Kidney Cancer at High Risk of Relapse After Cancer Surgery
Clinical Trials Co-Investigated by Robert J. Motzer
- A Phase I/II Study of Immunotherapy with MEDI0680 (AMP-514) Alone or in Combination with MEDI4736 in Patients with Advanced Kidney Cancer
- A Phase II Study of Brentuximab Vedotin to Treat Recurrent or Persistent Germ Cell Tumors
- A Phase II Study of Nivolumab with Ipilimumab or BMS-986016 Immunotherapy to Treat Advanced Kidney Cancer
- A Phase III Study Comparing Conventional-Dose Chemotherapy with High-Dose Chemotherapy for Persistent or Recurrent Germ Cell Tumors
- A Pilot Study of Nivolumab Immunotherapy Given Before Surgery in Patients with High-Risk, Non-Metastatic Kidney Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more